{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T10:29:21Z","timestamp":1783592961235,"version":"3.55.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T00:00:00Z","timestamp":1745884800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T00:00:00Z","timestamp":1745884800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"DOI":"10.1186\/s13063-024-08710-9","type":"journal-article","created":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T15:10:16Z","timestamp":1745939416000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Clinical Study Reports\u2014a systematic review with thematic synthesis: Part 1. History, contents and structure, definitions, and terminology"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1139-655X","authenticated-orcid":false,"given":"J. K.","family":"Aronson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2420-0811","authenticated-orcid":false,"given":"I. J.","family":"Onakpoya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,29]]},"reference":[{"issue":"9","key":"8710_CR1","doi-asserted-by":"publisher","first-page":"e1002127","DOI":"10.1371\/journal.pmed.1002127","volume":"13","author":"S Golder","year":"2016","unstructured":"Golder S, Loke YK, Wright K, Norman G. Reporting of adverse events in published and unpublished studies of health care interventions: a systematic review. PLoS Med. 2016;13(9):e1002127.","journal-title":"PLoS Med"},{"issue":"1","key":"8710_CR2","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1186\/s13063-016-1327-z","volume":"17","author":"A Hodkinson","year":"2016","unstructured":"Hodkinson A, Gamble C, Smith CT. Reporting of harms outcomes: a comparison of journal publications with unpublished clinical study reports of orlistat trials. Trials. 2016;17(1):207.","journal-title":"Trials"},{"key":"8710_CR3","unstructured":"World Health Organization. An international information system on the quality, safety, and efficacy of drugs. WHO Chron 1973;27(7): 320\u20132."},{"key":"8710_CR4","volume-title":"Clinical Trials","author":"B Spilker","year":"1991","unstructured":"Spilker B. Clinical Trials. New York: Raven Press; 1991."},{"key":"8710_CR5","unstructured":"Meinert CL. Clinical Trials Dictionary. Terminology and Usage Recommendations. Baltimore, Maryland: The Johns Hopkins University School of Hygiene and Public Health Center for Clinical Trials, 1996."},{"key":"8710_CR6","first-page":"329","volume-title":"Detection of New Adverse Drug Reactions","author":"JCC Talbot","year":"1998","unstructured":"Talbot JCC. Pharmacovigilance regulations and guidelines and the International Conference on Harmonisation. In: Stephens MDB, Talbot JCC, Routledge PA, editors. Detection of New Adverse Drug Reactions. 4th ed. Grove\u2019s Dictionaries Inc.; 1998. p. 329\u201348.","edition":"4"},{"key":"8710_CR7","unstructured":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals For Human Use. ICH Harmonised Tripartite Guideline. Structure and content of clinical study reports. E3. Step 4 (final); 30 November 1995. https:\/\/database.ich.org\/sites\/default\/files\/E3_Guideline.pdf."},{"key":"8710_CR8","unstructured":"ICH E3 Guideline: Structure and Content of Clinical Study Reports Questions & Answers (R1) [2012 July 6]. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/international-conference-harmonisation-technical-requirements-registration-pharmaceuticals-human-use-ich-guideline-e3-questions-and-answers-r1_en.pdf."},{"issue":"1","key":"8710_CR9","first-page":"74","volume":"28","author":"H Ebina","year":"2019","unstructured":"Ebina H, Colquhoun J. Clinical trial disclosure landscape and awareness in Japan. Medical writing. 2019;28(1):74\u20137.","journal-title":"Medical Writing"},{"key":"8710_CR10","volume-title":"How Science Takes Stock","author":"M Hunt","year":"1997","unstructured":"Hunt M. How Science Takes Stock. The Story of Meta-Analysis. New York: Russell Sage Foundation; 1997."},{"key":"8710_CR11","unstructured":"Catalogue of Bias Collaboration, Devito N, Goldacre B. Publication bias. In: Catalogue Of Bias. 2019. https:\/\/catalogofbias.org\/biases\/publication-bias."},{"issue":"3","key":"8710_CR12","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1056\/NEJMsa065779","volume":"358","author":"EH Turner","year":"2008","unstructured":"Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med. 2008;358(3):252\u201360. https:\/\/doi.org\/10.1056\/NEJMsa065779.","journal-title":"N Engl J Med"},{"issue":"8746","key":"8710_CR13","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1016\/0140-6736(91)90201-y","volume":"337","author":"PJ Easterbrook","year":"1991","unstructured":"Easterbrook PJ, Berlin JA, Gopalan R, Matthews DR. Publication bias in clinical research. Lancet. 1991;337(8746):867\u201372. https:\/\/doi.org\/10.1016\/0140-6736(91)90201-y.","journal-title":"Lancet"},{"key":"8710_CR14","doi-asserted-by":"publisher","first-page":"b5106","DOI":"10.1136\/bmj.b5106","volume":"339","author":"T Jefferson","year":"2009","unstructured":"Jefferson T, Jones M, Doshi P, Del Mar C. Neuraminidase inhibitors for preventing and treating influenza in healthy adults: systematic review and meta-analysis. BMJ. 2009;339:b5106.","journal-title":"BMJ"},{"issue":"348","key":"8710_CR15","doi-asserted-by":"publisher","first-page":"g2545","DOI":"10.1136\/bmj.g2545","volume":"9","author":"T Jefferson","year":"2014","unstructured":"Jefferson T, Jones M, Doshi P, Spencer EA, Onakpoya I, Heneghan CJ. Oseltamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments. BMJ. 2014;9(348):g2545. https:\/\/doi.org\/10.1136\/bmj.g2545.","journal-title":"BMJ"},{"issue":"348","key":"8710_CR16","doi-asserted-by":"publisher","first-page":"g2547","DOI":"10.1136\/bmj.g2547","volume":"9","author":"CJ Heneghan","year":"2014","unstructured":"Heneghan CJ, Onakpoya I, Thompson M, Spencer EA, Jones M, Jefferson T. Zanamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments. BMJ. 2014;9(348):g2547. https:\/\/doi.org\/10.1136\/bmj.g2547.","journal-title":"BMJ"},{"issue":"2","key":"8710_CR17","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1179\/2047480614Z.000000000211","volume":"23","author":"S Hamilton","year":"2014","unstructured":"Hamilton S. Effective authoring of clinical study reports: 1. Companion guide Medical Writing. 2014;23(2):86\u201392.","journal-title":"Medical Writing"},{"key":"8710_CR18","unstructured":"Hodkinson AJ. Reporting of harms in clinical study reports\u2014case study. In: Assessments of harms in clinical trials. PhD Thesis, Chapter 3. University of Liverpool, 2015: 53\u201391."},{"key":"8710_CR19","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1177\/009286159903300318","volume":"33","author":"B Warner","year":"1999","unstructured":"Warner B. A master format for clinical reports. Drug Inf J. 1999;33:785\u20138.","journal-title":"Drug Inf J"},{"issue":"5","key":"8710_CR20","doi-asserted-by":"publisher","first-page":"e068981","DOI":"10.1136\/bmjopen-2022-068981","volume":"13","author":"D Byrne","year":"2023","unstructured":"Byrne D, Prendergast C, Fahey T, Moriarty F. Clinical study reports published by the European Medicines Agency 2016\u20132018: a cross-sectional analysis. BMJ Open. 2023;13(5):e068981. https:\/\/doi.org\/10.1136\/bmjopen-2022-068981.","journal-title":"BMJ Open"},{"issue":"2","key":"8710_CR21","doi-asserted-by":"publisher","first-page":"e002496","DOI":"10.1136\/bmjopen-2012-002496","volume":"3","author":"P Doshi","year":"2013","unstructured":"Doshi P, Jefferson T. Clinical study reports of randomised controlled trials: an exploratory review of previously confidential industry reports. BMJ Open. 2013;3(2):e002496. https:\/\/doi.org\/10.1136\/bmjopen-2012-002496.","journal-title":"BMJ Open"},{"key":"8710_CR22","unstructured":"PHUSE Safety Analytics Working Group. Data Listings in Clinical Study Reports. PHUSE WP-061, Version 1.0. 23 November 2021. https:\/\/phuse.s3.eu-central-1.amazonaws.com\/Deliverables\/Safety+Analytics\/WP061.pdf."},{"issue":"3","key":"8710_CR23","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1002\/pst.2286","volume":"22","author":"M Navarro","year":"2023","unstructured":"Navarro M, Brucken N, Yang A, Ball G. Just say no to data listings! Pharm Stat. 2023;22(3):581\u20134. https:\/\/doi.org\/10.1002\/pst.2286. Epub 2023 Jan 3.","journal-title":"Pharm Stat"},{"key":"8710_CR24","doi-asserted-by":"publisher","unstructured":"Bhardwaj P, Sinha S, Yadav RK. Medical and scientific writing: time to go lean and mean. Perspect Clin Res 2017;8(3): 113\u2013117. https:\/\/doi.org\/10.4103\/picr.PICR_11_17.","DOI":"10.4103\/picr.PICR_11_17"},{"issue":"6","key":"8710_CR25","doi-asserted-by":"publisher","first-page":"871","DOI":"10.3325\/cmj.2007.6.871","volume":"48","author":"V Alfaro","year":"2007","unstructured":"Alfaro V, Cullell-Young M, Tanovic A. Abbreviated clinical study reports with investigational medicinal products for human use: current guidelines and recommendations. Croat Med J. 2007;48(6):871\u20137. https:\/\/doi.org\/10.3325\/cmj.2007.6.871.","journal-title":"Croat Med J"},{"issue":"9","key":"8710_CR26","first-page":"6","volume":"17","author":"JL Chamberlain","year":"2020","unstructured":"Chamberlain JL, Drees B. Do we need to involve patients in clinical study report lay summaries? Regulatory Rapporteur. 2020;17(9):6\u20137.","journal-title":"Regulatory Rapporteur"},{"key":"8710_CR27","doi-asserted-by":"publisher","unstructured":"Rifai N, Annesley TM, Berg JP, Brugnara C, Delvin E, Lamb EJ, Ness PM, Plebani M, Wick MR, Wu A, Delanghe J. An appeal to medical journal editors: the need for a full description of laboratory methods and specimen handling in clinical study reports. Statement by the Consortium of Laboratory Medicine Journal Editors. Ann Clin Biochem 2012; 49(Pt 2): 105\u20137. https:\/\/doi.org\/10.1258\/acb.2011.201201. Epub 2012 Feb 1.","DOI":"10.1258\/acb.2011.201201"},{"issue":"6","key":"8710_CR28","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1208\/s12248-022-00762-6","volume":"24","author":"D Jani","year":"2022","unstructured":"Jani D, Marsden R, Gunsior M, Hay LS, Ward B, Cowan KJ, Azadeh M, Barker B, Cao L, Closson KR, Coble K, Dholakiya SL, Dusseault J, Hays A, Herl C, Hodsdon ME, Irvin SC, Kirshner S, Kolaitis G, Kulagina N, Kumar S, Lai CH, Lipari F, Liu S, Merdek KD, Moldovan IR, Mozaffari R, Pan L, Place C, Snoeck V, Manning MS, Stocker D, Tary-Lehmann M, Turner A, Vainshtein I, Verthelyi D, Williams WT, Yan H, Yan W, Yang L, Yang L, Zemo J, Zhong ZD. Anti-drug antibody sample testing and reporting harmonization. AAPS J. 2022;24(6):113. https:\/\/doi.org\/10.1208\/s12248-022-00762-6.","journal-title":"AAPS J"},{"key":"8710_CR29","doi-asserted-by":"crossref","unstructured":"Talbot, J Keisu M, St\u00e5hle L. Clinical trials\u2014collecting safety data and establishing the adverse drug reactions profile. In: Talbot J, Aronson JK (editors). Stephens\u2019 Detection and Evaluation of Adverse Drug Reactions: Principles and Practice. 6th edition, Chapter 4. Oxford: Wiley-Blackwell, 2011: 215\u201389.","DOI":"10.1002\/9780470975053.ch4"},{"key":"8710_CR30","doi-asserted-by":"publisher","unstructured":"McGauran N, Wieseler B. Centralised full access to clinical study data can support unbiased guideline development, continuing medical education, and patient information. J Eur CME 2021; 10(1): 1989172. https:\/\/doi.org\/10.1080\/21614083.2021.1989172. eCollection 2021.","DOI":"10.1080\/21614083.2021.1989172"},{"key":"8710_CR31","unstructured":"US Food and Drug Administration. E3 structure and content of clinical study reports. July 1996. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/e3-structure-and-content-clinical-study-reports."},{"key":"8710_CR32","unstructured":"Health Canada. Drugs Directorate, International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Structure and Content of Clinical Study Reports: ICH Harmonised Tripartite Guideline. Drugs Directorate, Health Canada, 1996."},{"key":"8710_CR33","doi-asserted-by":"publisher","unstructured":"Bastian H. What the systematic review of HPV vaccine clinical study reports does, and does not, reveal: commentary on J\u00f8rgensen et al. Syst Rev 2020 Feb 28; 9(1): 41. https:\/\/doi.org\/10.1186\/s13643-020-01299-5.","DOI":"10.1186\/s13643-020-01299-5"},{"key":"8710_CR34","unstructured":"MMS Blog. Navigating the four types of clinical study reports. https:\/\/www.mmsholdings.com\/navigating-the-four-types-of-clinical-study-reports."},{"key":"8710_CR35","unstructured":"European Medicines Agency. ICH Guideline E2F on development safety update reports. Step 5. September 2011. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/ich-guideline-e2f-development-safety-update-report-step-5_en.pdf."},{"key":"8710_CR36","unstructured":"European Medicines Agency. Policy\/0043 on access to documents (related to medicinal products for human and veterinary use). 2010. https:\/\/www.ema.europa.eu\/en\/documents\/other\/policy-43-european-medicines-agency-policy-access-documents_en.pdf."},{"key":"8710_CR37","unstructured":"European Medicines Agency. Draft policy\/0070: Publication and access to clinical-trial data. 2013. https:\/\/www.ema.europa.eu\/en\/documents\/other\/draft-policy-70-publication-and-access-clinical-trial-data_en.pdfE6_R1\/Step4\/E6_R1__Guideline.pdf"},{"key":"#cr-split#-8710_CR38.1","unstructured":"European Medicines Agency. Press Release. European Medicines Agency to push ahead in 2014 towards publication and access to clinical trial data. EMA\/780089\/2013"},{"key":"#cr-split#-8710_CR38.2","unstructured":"17 December 2013. https:\/\/www.ema.europa.eu\/en\/documents\/press-release\/european-medicines-agency-push-ahead-2014-towards-publication-and-access-clinical-trial-data_en.pdf."},{"key":"8710_CR39","unstructured":"European Medicines Agency. Press Release. Publication of clinical reports. EMA adopts landmark policy to take effect on 1 January 2015. 2 October 2014. EMA\/601455\/2014. https:\/\/www.ema.europa.eu\/en\/documents\/press-release\/publication-clinical-reports_en.pdf."},{"key":"8710_CR40","unstructured":"US Food and Drug Administration. Clinical data summary pilot program. 2018. Update 26 March 2020. https:\/\/www.fda.gov\/drugs\/development-approval-process-drugs\/clinical-data-summary-pilot-program."},{"key":"8710_CR41","unstructured":"US Food and Drug Administration. FDA continues to support transparency and collaboration in drug approval process as the clinical data summary pilot concludes. 26 March 2020. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-continues-support-transparency-and-collaboration-drug-approval-process-clinical-data-summary."},{"key":"8710_CR42","unstructured":"Government of Canada. Gouvernement du Canada. Overview of Vanessa's Law. 4 July 2023. https:\/\/www.canada.ca\/en\/health-canada\/services\/drugs-health-products\/legislation-guidelines\/overview-vannessa-law-protecting-canadians-unsafe-drugs-act-vanessa-law-amendments-food-drugs-act.html."},{"key":"8710_CR43","unstructured":"European Federation of Pharmaceutical Industries and Associations. EFPIA and PhRMA release joint principles for responsible clinical trial data sharing to benefit patients. https:\/\/www.efpia.eu\/news-events\/the-efpia-view\/statements-press-releases\/130724-efpia-and-phrma-release-joint-principles-for-responsible-clinical-trial-data-sharing-to-benefit-patients."},{"key":"8710_CR44","unstructured":"PhRMA. Principles for responsible clinical trial data sharing; June 2023. https:\/\/phrma.org\/resource-center\/Topics\/Clinical-Trials\/PhRMA-Principles-for-Clinical-Trial-Data-Sharing."},{"key":"8710_CR45","doi-asserted-by":"publisher","first-page":"l4127","DOI":"10.1136\/bmj.l4127","volume":"366","author":"J Miller","year":"2019","unstructured":"Miller J, Ross JS, Wilenzick M, Mello MM. Sharing of clinical trial data and results reporting practices among large pharmaceutical companies: cross sectional descriptive study and pilot of a tool to improve company practices. BMJ. 2019;366:l4127. https:\/\/doi.org\/10.1136\/bmj.l4127.","journal-title":"BMJ"},{"key":"8710_CR46","doi-asserted-by":"publisher","unstructured":"J\u00f8rgensen L, G\u00f8tzsche PC, Jefferson T. Benefits and harms of the human papillomavirus (HPV) vaccines: comparison of trial data from clinical study reports with corresponding trial register entries and journal publications. Syst Rev 2020; 9(1). https:\/\/doi.org\/10.1186\/s13643-020-01300-1.","DOI":"10.1186\/s13643-020-01300-1"},{"key":"8710_CR47","doi-asserted-by":"publisher","unstructured":"Lehmann S, Allard R, Boehler YB. The European Medicines Agency clinical data website enables insights into clinical development timelines and strategy. Open Access Journal of Clinical Trials 2019: 37\u201356. https:\/\/doi.org\/10.2147\/OAJCT.S205842.","DOI":"10.2147\/OAJCT.S205842"},{"issue":"3","key":"8710_CR48","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1017\/jme.2021.67","volume":"49","author":"AC Egilman","year":"2021","unstructured":"Egilman AC, Kapczynski A, McCarthy ME, Luxkaranayagam AT, Morten CJ, Herder M, Wallach JD, Ross JS. Transparency of regulatory data across the European Medicines Agency, Health Canada, and US Food and Drug Administration. J Law Med Ethics. 2021;49(3):456\u201385. https:\/\/doi.org\/10.1017\/jme.2021.67.","journal-title":"J Law Med Ethics"},{"issue":"4","key":"8710_CR49","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1161\/CIRCOUTCOMES.114.001166","volume":"7","author":"HM Krumholz","year":"2014","unstructured":"Krumholz HM, Gross CP, Blount KL, Ritchie JD, Hodshon B, Lehman R, Ross JS. Sea change in open science and data sharing: leadership by industry. Circ Cardiovasc Qual Outcomes. 2014;7(4):499\u2013504. https:\/\/doi.org\/10.1161\/CIRCOUTCOMES.114.001166.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"8710_CR50","doi-asserted-by":"publisher","unstructured":"Navar AM, Pencina MJ, Rymer JA, Louzao DM, Peterson ED. Use of open access platforms for clinical trial data. JAMA 2016 Mar 22\u201329; 315(12): 1283\u20134. https:\/\/doi.org\/10.1001\/jama.2016.2374. Erratum in: JAMA 2016 Jun 14; 315(22): 2472.","DOI":"10.1001\/jama.2016.2374"},{"issue":"18","key":"8710_CR51","doi-asserted-by":"publisher","first-page":"4436","DOI":"10.3390\/cancers15184436","volume":"15","author":"C Berking","year":"2023","unstructured":"Berking C, Livingstone E, Debus D, Loquai C, Weichenthal M, Leiter U, Kiecker F, Mohr P, Eigentler TK, Remy J, Schober K, Heppt MV, von Wasielewski I, Schadendorf D, Gutzmer R. COMBI-r: a prospective, non-interventional study of dabrafenib plus trametinib in unselected patients with unresectable or metastatic BRAF V600-mutant melanoma. Cancers (Basel). 2023;15(18):4436. https:\/\/doi.org\/10.3390\/cancers15184436.","journal-title":"Cancers (Basel)"},{"issue":"9","key":"8710_CR52","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1080\/13669877.2016.1200652","volume":"19","author":"D Way","year":"2016","unstructured":"Way D, Bouder F, L\u00f6fstedt R, Evensen D. Medicines transparency at the European Medicines Agency (EMA) in the new information age: the perspectives of patients. J Risk Res. 2016;19(9):1185\u2013215.","journal-title":"J Risk Res"},{"issue":"4","key":"8710_CR53","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1017\/err.2021.3","volume":"12","author":"E Hickey","year":"2021","unstructured":"Hickey E. We can only presume: relationship between protection of commercial interests and general presumptions of confidentiality shrouded in mist as Court of Justice upholds European Medicines Agency disclosure of clinical study reports. Eur J Risk Reg. 2021;12(4):871\u20138.","journal-title":"Eur J Risk Reg"},{"issue":"9","key":"8710_CR54","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1001\/jama.2017.0918","volume":"317","author":"AL Davis","year":"2017","unstructured":"Davis AL, Miller JD. The European Medicines Agency and publication of clinical study reports: a challenge for the US FDA. JAMA. 2017;317(9):905\u20136. https:\/\/doi.org\/10.1001\/jama.2017.0918.","journal-title":"JAMA"},{"key":"8710_CR55","doi-asserted-by":"publisher","unstructured":"Stefanini E. Publication of clinical trials data: a new approach to transparency in the European Legislative Framework. Med Access @ Point of Care 2017; (1): e98-e103. https:\/\/doi.org\/10.5301\/maapoc.0000018","DOI":"10.5301\/maapoc.0000018"},{"issue":"12","key":"8710_CR56","doi-asserted-by":"publisher","first-page":"e017917","DOI":"10.1136\/bmjopen-2017-017917","volume":"7","author":"JE Miller","year":"2017","unstructured":"Miller JE, Wilenzick M, Ritcey N, Ross JS, Mello MM. Measuring clinical trial transparency: an empirical analysis of newly approved drugs and large pharmaceutical companies. BMJ Open. 2017;7(12):e017917. https:\/\/doi.org\/10.1136\/bmjopen-2017-017917.","journal-title":"BMJ Open"},{"key":"8710_CR57","doi-asserted-by":"publisher","unstructured":"Goldacre B, Lane S, Mahtani KR, Heneghan C, Onakpoya I, Bushfield I, Smeeth L. Pharmaceutical companies' policies on access to trial data, results, and methods: audit study. BMJ. 2017; 358:j 3334. https:\/\/doi.org\/10.1136\/bmj.j3334.","DOI":"10.1136\/bmj.j3334"},{"key":"8710_CR58","doi-asserted-by":"publisher","first-page":"111263","DOI":"10.1016\/j.jclinepi.2024.111263","volume":"167","author":"AM Hopkins","year":"2024","unstructured":"Hopkins AM, Modi ND, Rockhold FW, Hoffmann T, Menz BD, Veroniki AA, McKinnon RA, Rowland A, Swain SM, Ross JS, Sorich MJ. Accessibility of clinical study reports supporting medicine approvals: a cross-sectional evaluation. J Clin Epidemiol. 2024;167:111263. https:\/\/doi.org\/10.1016\/j.jclinepi.2024.111263. (Epub 2024 Jan 13).","journal-title":"J Clin Epidemiol"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-024-08710-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-024-08710-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-024-08710-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T15:10:42Z","timestamp":1745939442000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-024-08710-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,29]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["8710"],"URL":"https:\/\/doi.org\/10.1186\/s13063-024-08710-9","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,29]]},"assertion":[{"value":"29 April 2025","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"141"}}